The historical rank and industry rank for Medigen Biotechnology's OCF Margin % or its related term are showing as below:
ROCO:3176'
s OCF Margin % Range Over the Past 10 Years
Min: -135.47 Med: -97.41 Max: 13.21
Current: 2.56
During the past 13 years, the highest OCF Margin % of Medigen Biotechnology was 13.21%. The lowest was -135.47%. And the median was -97.41%.
ROCO:3176's OCF Margin % is ranked better than 70.49% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs ROCO:3176: 2.56
Medigen Biotechnology OCF Margin % Related Terms
Medigen Biotechnology OCF Margin % Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Medigen Biotechnology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a OCF Margin % of 41.69% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medigen Biotechnology and its competitors. According to the industry distribution chart, Medigen Biotechnology ranks #283 out of 959 companies in the Biotechnology industry, placing it in the top 29.5%.
Is Medigen Biotechnology's OCF Margin % too high?
Medigen Biotechnology's current OCF Margin % is 41.69%. Based on the distribution chart, Medigen Biotechnology ranks #283 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Biotechnology has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #283 out of 959 companies for OCF Margin %. This puts Medigen Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current OCF Margin % is 41.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.25, compared to a current price of NT$33.40 — trading 32.2% below its estimated fair value. The current OCF Margin % is 41.69%. Medigen Biotechnology's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current OCF Margin % is 41.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$33.40 is trading 32.2% below its estimated GF Value™ of NT$49.25.
GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.
Key valuation signals for ROCO:3176:
OCF Margin %: 41.69%
GF Value™: NT$49.25 vs. price of NT$33.40 (32.2% below fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
54GF Score
Get the complete analysis for ROCO:3176
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
